|
Journal of Postgraduate Medicine, Vol. 47, Issue 4, 2001 pp.282 Letter to the Editor Amphotericin B Induced Ventricular Arrhythmia and Its Relation to Central Venous Line Chongtham DS, Singh MM*, Ram T Departments of Internal Medicine, and Community Medicine*, Post-graduate Institute of Medical Education and Research, Chandigarh-160 012. Code Number: jp01083 Sir, A 40-year-old man, weighing 81 kg, with no previous history of
heart disease presented with complaint of fever since 25 days. Ultrasonography
and computed tomography of abdomen showed altered echotexture and multiple splenic
hypodense lesions. Aspiration and culture showed the growth of Candida tropicalis
and a rising serological titre from 1:256 to 1:1024. The patient was started
on intravenous amphotericin B 8 mg (0.1 mg/kg body weight) over three hours
after a test dose of 1 mg. After a cumulative dose of 28 mg, he developed a
life-threatening ventricular tachycardia which was DC-verted to normal sinus
rhythm. Right and left ventricular functions were normal. The patient was
neither on any other cardiotonic drug nor was there any evidence of organic
heart disease. His concomitant serum potassium was 4 mEq/l, serum sodium 140
mEq/L, serum creatinine 1.4mg/dL and serum calcium was 10mg/dl. Amphotericin B was withhold for a day without shifting the central
venous line and it was observed that ventricular tachycardia disappeared. Slow
re-challenging with liposomal amphotericin with 0.1mg/kg dose led to development
of ill-sustained, self-limiting ventricular tachycardia after receiving 4mg.
The drug was again withhold. Echocardiography showed that the tip of the central
venous line was just above the right atrium. After withdrawing the line by about
6 cms., liposomal amphotericin followed by conventional amphotericin B was restarted
up to a cumulative dose of 1 gm without any further cardiac toxicity. Liver
biopsy was done subsequently and reported as non-Hodgkins lymphoma. Despite
adequate treatment, the patient succumbed to overwhelming sepsis. Amphotericin B therapy in patients with abnormal serum potassium
or renal function have been described to have life-threatening ventricular arrhythmias(1)
including premature ventricular contractions(2) and also bradycardia.(3) Ventricular
arrhythmia have been reported after rapid infusion of large doses of amphotericin
B in patients with renal failure or hyperkalaemia but not in patients with normal
serum creatinine and potassium, even when infused over one hour.(1) In our case,
there seems to be a close relationship between high concentration of amphotericin
at the SVC-RA junction and development of ventricular arrhythmia. The possible
reason could be reversible concentration-dependent loss of intracellular potassium
as documented in vitro.(2) There is no absolute consensus on how amphotericin B should be
administered.(4) Administration of the drug through central venous line has
been documented for testing the stability of amphotericin B in 5+ACU-dextrose
injection.(5) The present case demonstrates thwarting of the potential danger
of fatal arrhythmia during amphotericin infusion on central venous line placed
near the heart by repositioning the line away from the heart when no other obvious
cause is found. References
This article is also available in full-text from http://www.jpgmonline.com/ © Copyright 2001 - Journal of Postgraduate Medicine |
|